James Sigler - Finch Therapeutics Ex CMC
Insider
James Sigler is Ex CMC of Finch Therapeutics Group
| Age | 63 |
| Phone | 617 229 6499 |
| Web | https://www.finchtherapeutics.com |
Finch Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2194) % which means that it has lost $0.2194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6264) %, meaning that it created substantial loss on money invested by shareholders. Finch Therapeutics' management efficiency ratios could be used to measure how well Finch Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Finch Therapeutics Group currently holds 30.13 M in liabilities with Debt to Equity (D/E) ratio of 0.35, which is about average as compared to similar companies. Finch Therapeutics has a current ratio of 7.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Finch Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Finch Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Finch Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Finch to invest in growth at high rates of return. When we think about Finch Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Joan Wood | Stoke Therapeutics | N/A | |
| Sean Jeffries | Design Therapeutics | 45 | |
| MD MBA | Kiora Pharmaceuticals | 52 | |
| Michelle Zhang | Ikena Oncology | N/A | |
| Sharon Townson | Monte Rosa Therapeutics | 50 | |
| Joo MD | Design Therapeutics | 61 | |
| Jeffrey Ecsedy | Ikena Oncology | 55 | |
| Brian Sullivan | Celcuity LLC | 63 | |
| Chulani Karunatilake | Werewolf Therapeutics | 65 | |
| Ajim CFA | Monte Rosa Therapeutics | 47 | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Julie CPA | Design Therapeutics | N/A | |
| MD FACC | Longeveron LLC | 62 | |
| Kelly Schick | C4 Therapeutics | 45 | |
| Uli Bialucha | Xilio Development | N/A | |
| Dawn Giangiulio | Design Therapeutics | N/A | |
| Randi MD | Werewolf Therapeutics | 69 | |
| MBA MD | Ikena Oncology | 59 | |
| Eric Rojas | Stoke Therapeutics | N/A | |
| Alfredo Castro | Ikena Oncology | N/A | |
Management Performance
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.22 |
Finch Therapeutics Leadership Team
Elected by the shareholders, the Finch Therapeutics' board of directors comprises two types of representatives: Finch Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Finch. The board's role is to monitor Finch Therapeutics' management team and ensure that shareholders' interests are well served. Finch Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Finch Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Chief Officer | ||
| Lance CPA, Chief Officer | ||
| Bryan MBA, Chief Officer | ||
| Sonia Timberlake, VP Research | ||
| CFA CFA, Principal COO | ||
| Mark Smith, CEO Director | ||
| Alka Batycky, Chief Officer | ||
| JD Esq, Chief Sec | ||
| Matthew JD, Chief Officer | ||
| James Sigler, Ex CMC | ||
| James MBA, Executive CMC |
Finch Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Finch Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 10.74 M | ||||
| Shares Outstanding | 1.61 M | ||||
| Shares Owned By Insiders | 53.48 % | ||||
| Shares Owned By Institutions | 11.35 % | ||||
| Number Of Shares Shorted | 19.2 K | ||||
| Price To Book | 0.14 X | ||||
| Price To Sales | 30.46 X | ||||
| Revenue | 107 K |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Finch Pink Sheet
If you are still planning to invest in Finch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Finch Therapeutics' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Stocks Directory Find actively traded stocks across global markets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |